Evidence map›Paper›PMID 40627166›Full record

ArticleCurrent microbiology2025

Optimization of Serratiopeptidase Production from Serratia marcescens SP6 Using Sequential Strategy of Experimental Designs.

Sejal Kumar, Sourav Bhattacharya

Abstract read
PubMed Publisher
In one paragraph

Article in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. International journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Sejal KumarDepartment of Microbiology and Botany, School of Sciences, JAIN (Deemed-to-be University), 34, 1st Cross, J.C. Road, Bangalore, Karnataka, 560027, India.
Sourav BhattacharyaDepartment of Microbiology and Botany, School of Sciences, JAIN (Deemed-to-be University), 34, 1st Cross, J.C. Road, Bangalore, Karnataka, 560027, India. bhattsourav3011@gmail.com.ORCID http://orcid.org/0000-0001-7920-3609

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Serratiopeptidase, a fibrinolytic and anti-inflammatory biological macromolecule is in high demand for its therapeutic applications. Thus, exploration of novel enzyme sources with high-yielding serratiopeptidase fermentation capability is necessary. The present study attempts to maximize serratiopeptidase synthesis from Serratia marcescens SP6 by optimizing the fermentation conditions using sequential strategy of experimental designs. Of the 11 fermentation parameters evaluated under one-factor-at-a-time approach and Plackett-Burman design, 3 parameters namely dextrose, casein, and initial pH of medium significantly influenced serratiopeptidase production (p < 0.0001). These were evaluated further by the central composite rotatable design of response surface methodology to determine the effects of their interaction on serratiopeptidase production. Post-optimization, 2489.71 U/mL was predicted as the maximum serratiopeptidase activity at conditions of 10 g/L of casein, 18.40 g/L of dextrose, and pH 7 of fermentation broth. Upon experimental evaluation of the assay conditions, 2495 U/mL of serratiopeptidase activity was recorded which is in good agreement with the predicted response. An overall increase of 10.16-fold in the enzyme production was thus achieved from the unoptimized condition. The findings from this sequential optimization method of enzyme synthesis demonstrated the applicability of the predicted optimum conditions for sustainable large-scale serratiopeptidase production from Serratia marcescens SP6.

Indexed as

Bacterial ProteinsPeptide HydrolasesSerratia marcescensCaseinsCulture MediaFermentationGlucoseHydrogen-Ion ConcentrationBacterial ProteinsCaseinsCulture MediaGlucosePeptide Hydrolasesserratiopeptidase

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.